compared the mutational profiles between TNBC and HR+/HER2- breast cancer and found that the mutation rate of PIK3CA in TNBC was 8.3%, significantly lower than in HR+/HER2- breast cancer (36.4%), indicating a differential distribution across subtypes (18). This evidence concerns the gene PIK3CA and breast carcinoma.